Thymosin fraction 5 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
== Additional information == During energy transformations in living systems, order and organization must be compensated by releasing energy which will increase entropy of the surrounding. Organisms are open systems that exchange materials and energy with the environment. They are never at equilibrium with the surrounding. Energy is spent to create and maintain order in the cells, and surplus energy and other simpler by-products are released to create disorder such that there is an increase in entropy of the surrounding. In a reversible process, entropy remains constant where as in an irreversible process (more common to real-world scenarios), entropy tends to increase. During phase changes (from solid to liquid, or to gas), entropy increases because the number of possible arrangements of particles increases. If ∆G<0, the chemical reaction is spontaneous and favourable in that direction. If ∆G=0, the reactants and products of chemical reaction are at equilibrium. If ∆G>0, the chemical reaction is non-spontaneous and unfavorable in that direction. ∆G is not an indicator for velocity or rate of chemical reaction at which equilibrium is reached. It depends on amount of enzyme and energy activation.
Hypermobility, also known as double-jointedness, describes joints that stretch farther than normal. For example, some hypermobile people can bend their thumbs backwards to their wrists, bend their knee joints backwards, put their leg behind the head, or perform other contortionist "tricks". It can affect one or more joints throughout the body. Hypermobile joints are common and occur in about 10 to 25% of the population. Most have no other issues. In a minority of people, pain and other symptoms are present. In some cases, hypermobile joints are a feature of connective tissue disorders. One of these, Ehlers-Danlos Syndrome, was classified into several types which have been found to be genetic. Hypermobile Ehlers–Danlos syndrome (hEDS), formerly called EDS Type 3, remains the only EDS variant without a diagnostic DNA test. In 2016 the diagnostic criteria for hEDS were re-written to be more restrictive, with the intent of narrowing the pool of hEDS patients, in the hope of making it easier to identify a common genetic mutation and create a diagnostic DNA test. At the same time, joint hypermobility syndrome was renamed as hypermobility spectrum disorder, and redefined as a hypermobility disorder that does not meet the diagnostic criteria for any heritable Connective Tissue Disorder (such as hEDS, other types of Ehlers–Danlos Syndrome, Marfan Syndrome, Loeys–Dietz Syndrome, or osteogenesis imperfecta).
First, the inward current becomes primarily carried by sodium channels. Second, the delayed rectifier, a potassium channel current, increases to 3.5 times its initial strength. In order for the transition from a calcium-dependent action potential to a sodium-dependent action potential to proceed new channels must be added to the membrane. If Xenopus neurons are grown in an environment with RNA synthesis or protein synthesis inhibitors that transition is prevented. Even the electrical activity of the cell itself may play a role in channel expression. If action potentials in Xenopus myocytes are blocked, the typical increase in sodium and potassium current density is prevented or delayed. This maturation of electrical properties is seen across species. Xenopus sodium and potassium currents increase drastically after a neuron goes through its final phase of mitosis. The sodium current density of rat cortical neurons increases by 600% within the first two postnatal weeks.
Phylum Chordata Subphylum Cephalochordata (Acraniata) – (lancelets; 32 species) Class Leptocardii (lancelets) Subphylum Tunicata (Urochordata) – (tunicates; 3,000 species) Class "Ascidiacea" (sea squirts; paraphyletic as thaliaceans are excluded) Class Thaliacea (salps, doliolids and pyrosomes) Class Appendicularia (larvaceans) Subphylum Vertebrata (Craniata) (vertebrates – animals with backbones; 66,100+ species) Infraphylum "Agnatha" paraphyletic (jawless vertebrates; 100+ species) Superclass Cyclostomata Class Myxinoidea or Myxini (hagfish; 85 species) Class Petromyzontida or Hyperoartia (lampreys; 53 species) Class †Conodonta Class †Myllokunmingiida Class †Pteraspidomorphi Class †Thelodonti Class †Anaspida Class †Cephalaspidomorphi Infraphylum Gnathostomata (jawed vertebrates) Class †"Placodermi" (Paleozoic armoured forms; paraphyletic in relation to all other gnathostomes) Class Chondrichthyes (cartilaginous fish; 900+ species) Class †"Acanthodii" (Paleozoic "spiny sharks"; paraphyletic in relation to Chondrichthyes) Class "Osteichthyes" (bony fish; 30,000+ species; paraphyletic when tetrapods are excluded) Subclass Actinopterygii (ray-finned fish; about 30,000 species) Clade "Sarcopterygii" (35,100+ species; paraphyletic when tetrapods are excluded – 8 species of lobe-finned fish) Class Actinistia (2 species) Class Dipnoi (6 species) Superclass Tetrapoda (four-limbed vertebrates; 35,100+ species) Class Amphibia (amphibians; 8,100+ species) Class Sauropsida (reptiles (including birds); 21,300+ species – 10,000+ species of birds and 11,300+ species of reptiles) Class Synapsida (mammals; 5,700+ species) Genus †Cathaymyrus Genus †Pikaia
Sources: en.wikipedia.org
=== Formulation and delivery === Delivery systems are primarily divided into polymer-based delivery systems (microspheres and liposomes) and live delivery systems (gram-positive bacteria, gram-negative bacteria and viruses)
== Technology applications == In its earliest form, liquid chromatography was used to separate the pigments of chlorophyll by a Russian botanist. Decades later, other chemists used the procedure for the study of carotins. Liquid chromatography was then used for the isolation of small molecules and organic compounds like amino acids, and most recently has been used in peptide and DNA research. Monolith columns have been instrumental in advancing the field of biomolecular research. In recent trade shows and international meetings for HPLC, interest in column monoliths and biomolecular applications has grown steadily, and this correlation is no coincidence. Monoliths have been shown to possess great potential in the “omics” fields- genomics, proteomics, metabolomics, and pharmacogenomics, among others. The reductionist approach to understanding the chemical pathways of the body and reactions to different stimuli, like drugs, are essential to new waves of healthcare like personalized medicine. Pharmacogenomics studies how responses to pharmaceutical products differ in efficacy and toxicity based on variations in the patient's genome; it is a correlation of drug response to gene expression in a patient. Jeremy K. Nicholson of the Imperial College, London, used a postgenomic viewpoint to understand adverse drug reactions and the molecular basis of human disesase. His group studied gut microbial metabolic profiles and were able to see distinct differences in reactions to drug toxicity and metabolism even among various geographical distributions of the same race.
20 September The Bermuda Triangle, a scientific explanation by geochemist Dr Richard McIver, from observations of mud volcanoes, and the oil and gas industries; Flight 19 left Fort Lauderdale in Florida on 5 December 1945; Charles Berlitz lived in Fort Lauderdale, and had written about the Triangle, and had an encounter with a cylindrical UFO next to a ship at night, where the ship engines and radio communications stopped; Lionel Beer of the British UFO Research Association, and a 1988 incident in Puerto where two military aircraft had intercepted a large triangular UFO, where witnesses claimed that both military aircraft were taken inside the UFO; Bilal U. Haq of the National Science Foundation claimed that all phenomena over the Bermuda Triangle had rational explanations; Colin Summerhayes was director of the Institute of Oceanographic Sciences in Wormley, Surrey (now the National Oceanography Centre); David Roberts of the Marine & Petroleum Geology journal; Richard Selley, head of geology at Imperial College; Yury Makagon of the Hydrocarbon and Environment Institute in Moscow, and methane hydrates were found in Dossor in 1928; Bill Dillon of the USGS at Woods Hole; reflection seismology; many oil rigs in the Caspian Sea had been sunk by blowouts, caused by disturbing hydrate sediments; the Ufa train disaster in June 1989; side-scan sonar.
"On the basis of creativity, and research and development, JEOL (日本電子) positively challenges the world’s highest technology thus forever contributing to the progress in both science and human society through its products." In commemoration of JEOL's 20th anniversary, the Kazato Research Foundation was created to support electron microscopy research. Kenji Kazato retired as president of JEOL in 1975, but continued to act as an adviser to the company until his death in 2012. Kazuo Ito was JEOL's president from 1982 to 1987. The Pittcon Heritage Award was posthumously awarded to them in 2016 for their contributions to scientific instrumentation. In 2014, a STEM resolution of 45 pm with a 300 kV microscope was first demonstrated with the atomic transmission electron microscope JEM-ARM300F.
==== Adverse effects ==== The common side effects associated with the use of Dronabinol are diverse but generally mild. They generally resolved in a few days. Common side effects include dizziness, dry mouth and headache. Others are related to an alteration of mental state, such as euphoria, mood changes, anxiety, drowsiness and abnormal thinking. Yet, impairment of cognitive performance, including memory and alertness, is not reported. The incidence of side effects may be reduced with a delayed dosing to near bedtime. Dose reduction should be considered in patients with continual side effects.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.